Sugi Predict

Sugi Predict / Compounds / SCHEMBL1105964

SCHEMBL1105964

SCHEMBL1105964

Cc1ncc(C(=O)O)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 2/20 0.47
▸ NAPRT Q6XQN6 1/20 0.47
▸ TTR P02766 1/20 0.47
▸ TSHR P16473 1/20 0.45
▸ SLC22A12 Q96S37 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ MGAM O43451 1/20 0.42
▸ P4HA1 P13674 2/20 0.41
▸ P4HTM Q9NXG6 2/20 0.41
▸ TPMT P51580 3/20 0.41
▸ SRD5A2 P31213 1/20 0.40
▸ PLAU P00749 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MIF P14174 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17294224 0.84 NAPRT (0.38) NAPRTTTRSLC22A12KDM4EALDH1A1
SCHEMBL2750787 0.84 KMT2A (0.43) NAPRTALDH1A1MEN1KMT2A
SCHEMBL31037449 0.82 LMNA (0.42) —
SCHEMBL20803764 0.82 KMT2A (0.37) NAPRTTTRTSHRSLC22A12KDM4E
SCHEMBL17151570 0.82 LMNA (0.42) —
SCHEMBL13748455 0.79 KMT2A (0.35) NAPRTTTRSLC22A12KDM4EALDH1A1
SCHEMBL17294344 0.79 ATM (0.51) KDM4EALDH1A1
SCHEMBL15047753 0.79 ALDH1A1 (0.38) KDM4EALDH1A1ALOX15HSD17B10MEN1
SCHEMBL846024 0.79 HCAR2 (0.50) HCAR2NAPRTKDM4EALDH1A1ALOX15
SCHEMBL232290 0.79 HCAR2 (0.50) HCAR2NAPRTTTRTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632910-B1 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2024-07-17 — — EP disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
US-11339147-B2 Lactam compound as FXR receptor agonist CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2022-05-24 — — US disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 — — US disclosed
US-20200190074-A1 LACTAM COMPOUND AS FXR RECEPTOR AGONIST MEDSHINE DISCOVERY INC. (CN) 2020-06-18 — — US disclosed
EP-3632910-A1 LACTAM COMPOUND AS FXR RECEPTOR AGONIST Medshine Discovery Inc. (CN) 2020-04-08 — — EP disclosed
CN-106536489-B Retinoid-related orphan receptor gamma modulators and uses thereof 葛兰素史密斯克莱知识产权发展有限公司 2020-02-07 — — CN disclosed
CN-107001342-B Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2020-02-07 — — CN disclosed
EP-3148987-B1 PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2019-01-02 — — EP disclosed
WO-2009141398-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2009-11-26 — — WO disclosed
CN-101522670-A Pyridin-3-yl derivatives as immunomodulators ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 — — CN disclosed
US-7314884-B2 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile HOFFMANN-LA ROCHE INC. (US) 2008-01-01 — — US disclosed
US-20070259925-A1 DPP IV INHIBITORS BOEHRINGER MARKUS 2007-11-08 — — US disclosed
CN-1713907-A N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors HOFFMANN LA ROCHE (CH) 2005-12-28 — — CN disclosed
US-20050096348-A1 DPP IV inhibitors BOEHRINGER MARKUS (CH) 2005-05-05 — — US disclosed
US-6861440-B2 DPP IV inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-03-01 — — US disclosed
EP-1441719-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-04 — — EP disclosed
US-20030130281-A1 DPP IV inhibitors HOFFMAN-LA ROCHE INC. 2003-07-10 — — US disclosed
WO-2003037327-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA-ROCHE AG (CH) 2003-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339147-B2 Lactam compound as FXR receptor agonist NR1H4, GPBAR1, SLC10A1 HCAR2 169/4885NAPRT 1433/4885TTR 4760/4885
US-20200190074-A1 LACTAM COMPOUND AS FXR RECEPTOR AGONIST NR1H4, GPBAR1, SLC10A1 HCAR2 169/4885NAPRT 1433/4885TTR 4760/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 HCAR2 279/4885NAPRT 1136/4885TTR 16/4885
US-20070259925-A1 DPP IV INHIBITORS DPP4, DPP3, DPP7 HCAR2 3091/4885NAPRT 2676/4885TTR 1694/4885
US-20030130281-A1 DPP IV inhibitors DPP4, DPP3, DPP7 HCAR2 3173/4885NAPRT 3236/4885TTR 2309/4885
US-20050096348-A1 DPP IV inhibitors DPP4, DPP3, DPP7 HCAR2 3091/4885NAPRT 2676/4885TTR 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.